Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of atezolizumab (an anti-PD-L1 monoclonal antibody), carboplatin (a platinum-based chemotherapeutic agent), and nab-paclitaxel (albumin-bound paclitaxel, a taxane chemotherapy). The regimen works through multiple mechanisms: atezolizumab blocks the PD-L1 protein, enhancing T-cell immune responses against cancer cells; carboplatin forms DNA crosslinks, interfering with cell division; and nab-paclitaxel stabilizes microtubules, preventing cancer cell division. This combination was approved by the FDA in December 2019 for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations.
- Brand names
- TecentriqAbraxane
- Other names
- atezolizumab + nab-paclitaxel + carboplatin
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on atezolizumab + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + carboplatin + nab-paclitaxel.